VOLUNTARY ANNOUNCEMENT - GLOBAL LAUNCH OF THE UPGRADED iMedLoop PLATFORM AND OPENING OF API SUBSCRIPTION
Filed with HKEX · Stock code 2526 · · 2 pages · English
Summary by 6ix AI
Hangzhou Diagens Biotechnology Co., Ltd. has announced the global launch of its upgraded iMedLoop platform and the opening of API subscriptions. The upgraded platform integrates advanced medical imaging capabilities and allows users to analyze imaging data without programming skills. This launch is seen as a significant step in expanding the company's business model and reaching international markets. The company aims to enhance health management through intelligent image interpretation services for a broader audience.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hangzhou Diagens Biotechnology Co., Ltd. on 6ix
Earlier from Hangzhou Diagens Biotechnology
- Voluntary announcement - significant progress achieved in the iMed-6.0 series medical imaging large model
- Voluntary announcement - entering into a strategic cooperation agreement with yongjiang laboratory
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Grant of options and restricted share units under the 2026 share incentive scheme
- Change of company logo
Follow Hangzhou Diagens Biotechnology into a list and get an email when it puts out news.
Follow Hangzhou Diagens Biotechnology